Sanofi/Regeneron's IO Springboard Libtayo Cleared For Skin Cancer
In addition to skin cancer, the PD-1 inhibitor cemiplimab is being positioned for a range of other tumor types with Phase III studies ongoing in lung and cervical cancers.
You may also be interested in...
Sanofi/Regeneron's PD-1 inhibitor Libtayo joins Keytruda and Tecentriq as the only PD-1/L1s approved by the US FDA as monotherapy for first-line non-small cell lung cancer.
Nine months after the US approval, the EU has followed suit and given a conditional approval for Sanofi and Regeneron’s IO Libtayo for a, so far, untreatable skin cancer.
Interview: Tesaro Chief Medical Officer Martin Huber addresses dostarlimab GARNET data and provides an update on integration with GlaxoSmithKline.